Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KYMR NASDAQ:LNTH NASDAQ:PTGX NASDAQ:RAPP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKYMRKymera Therapeutics$80.65+3.2%$83.40$28.06▼$103.00$6.43B2.06511,076 shs517,746 shsLNTHLantheus$96.09+3.4%$82.99$47.25▼$98.27$6.05B-0.081.01 million shs809,369 shsPTGXProtagonist Therapeutics$100.88+2.6%$101.13$45.05▼$107.84$6.33B1.89594,339 shs371,675 shsRAPPRapport Therapeutics$35.72+3.9%$33.32$7.73▼$42.27$1.64B0.82322,467 shs260,069 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKYMRKymera Therapeutics-1.92%-6.48%-10.91%-8.19%+158.74%LNTHLantheus-0.26%-3.47%+10.82%+27.14%+18.71%PTGXProtagonist Therapeutics-2.35%-1.58%-7.18%+18.53%+115.87%RAPPRapport Therapeutics-2.30%-7.71%-13.45%+17.71%+237.29%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKYMRKymera Therapeutics$80.65+3.2%$83.40$28.06▼$103.00$6.43B2.06511,076 shs517,746 shsLNTHLantheus$96.09+3.4%$82.99$47.25▼$98.27$6.05B-0.081.01 million shs809,369 shsPTGXProtagonist Therapeutics$100.88+2.6%$101.13$45.05▼$107.84$6.33B1.89594,339 shs371,675 shsRAPPRapport Therapeutics$35.72+3.9%$33.32$7.73▼$42.27$1.64B0.82322,467 shs260,069 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKYMRKymera Therapeutics-1.92%-6.48%-10.91%-8.19%+158.74%LNTHLantheus-0.26%-3.47%+10.82%+27.14%+18.71%PTGXProtagonist Therapeutics-2.35%-1.58%-7.18%+18.53%+115.87%RAPPRapport Therapeutics-2.30%-7.71%-13.45%+17.71%+237.29%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKYMRKymera Therapeutics 2.95Moderate Buy$118.1046.43% UpsideLNTHLantheus 2.73Moderate Buy$99.713.77% UpsidePTGXProtagonist Therapeutics 2.80Moderate Buy$113.6912.70% UpsideRAPPRapport Therapeutics 2.90Moderate Buy$56.8359.11% UpsideCurrent Analyst Ratings BreakdownLatest RAPP, KYMR, PTGX, and LNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026RAPPRapport Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$44.00 ➝ $56.005/15/2026PTGXProtagonist Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)5/11/2026LNTHLantheus Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$98.00 ➝ $115.005/8/2026LNTHLantheus CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/8/2026LNTHLantheus Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$85.00 ➝ $115.005/8/2026LNTHLantheus MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$95.00 ➝ $100.005/8/2026RAPPRapport Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$53.005/7/2026LNTHLantheus The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$94.005/6/2026PTGXProtagonist Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$110.005/6/2026PTGXProtagonist Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/6/2026KYMRKymera Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$106.00(Data available from 5/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKYMRKymera Therapeutics$39.21M169.20N/AN/A$18.72 per share4.31LNTHLantheus$1.54B4.06$6.60 per share14.55$18.62 per share5.16PTGXProtagonist Therapeutics$46.02M140.97N/AN/A$10.19 per share9.90RAPPRapport Therapeutics$20M85.42N/AN/A$9.86 per share3.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKYMRKymera Therapeutics-$311.35M-$3.57N/AN/AN/A-611.94%-24.71%-22.05%N/ALNTHLantheus$233.56M$4.1518.6517.83N/A18.05%29.32%15.00%8/5/2026 (Estimated)PTGXProtagonist Therapeutics-$130.15M-$1.81N/AN/AN/A-154.88%-17.76%-16.47%8/5/2026 (Estimated)RAPPRapport Therapeutics-$111.48M-$2.60N/AN/AN/AN/A-24.78%-23.44%8/6/2026 (Estimated)Latest RAPP, KYMR, PTGX, and LNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026LNTHLantheus$1.25$1.46+$0.21$1.80$354.48 million$377.33 million5/7/2026Q1 2026RAPPRapport Therapeutics-$0.56-$0.42+$0.14-$0.42$7.50 million$20.00 million5/5/2026Q1 2026PTGXProtagonist Therapeutics-$0.5004$0.05+$0.5504$0.05$11.70 million$56.37 million4/30/2026Q1 2026KYMRKymera Therapeutics-$0.89-$0.71+$0.18-$0.71$8.27 million$34.37 million3/10/2026Q4 2025RAPPRapport Therapeutics-$0.65-$0.72-$0.07-$0.72N/AN/A2/26/2026Q4 2025KYMRKymera Therapeutics-$0.77-$0.97-$0.20-$0.97$14.80 million$2.87 million2/26/2026Q4 2025LNTHLantheus$1.17$1.67+$0.50$0.82$367.03 million$406.79 million2/25/2026Q4 2025PTGXProtagonist Therapeutics-$0.53-$0.69-$0.16-$0.69$14.92 million$7.44 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKYMRKymera TherapeuticsN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ARAPPRapport TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKYMRKymera TherapeuticsN/A10.8110.81LNTHLantheus0.472.832.64PTGXProtagonist TherapeuticsN/A17.7617.76RAPPRapport TherapeuticsN/A27.0827.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKYMRKymera TherapeuticsN/ALNTHLantheus99.06%PTGXProtagonist Therapeutics98.63%RAPPRapport TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipKYMRKymera Therapeutics15.98%LNTHLantheus1.70%PTGXProtagonist Therapeutics5.19%RAPPRapport Therapeutics13.57%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKYMRKymera Therapeutics17082.26 million69.11 millionOptionableLNTHLantheus1,19365.11 million64.00 millionOptionablePTGXProtagonist Therapeutics12064.31 million60.97 millionOptionableRAPPRapport TherapeuticsN/A47.83 million41.34 millionN/ARAPP, KYMR, PTGX, and LNTH HeadlinesRecent News About These CompaniesRapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference4 hours ago | globenewswire.comUBS Group AG Sells 331,713 Shares of Rapport Therapeutics, Inc. $RAPPMay 20 at 6:38 AM | marketbeat.comRapport Therapeutics, Inc. (RAPP) Gets a Buy from JonesTradingMay 19 at 5:18 PM | theglobeandmail.comBTIG Keeps Their Buy Rating on Rapport Therapeutics, Inc. (RAPP)May 17 at 9:42 AM | theglobeandmail.comVanguard Group Inc. Acquires 191,219 Shares of Rapport Therapeutics, Inc. $RAPPMay 16, 2026 | marketbeat.comRock Ventures L.P. Third Sells 133,618 Shares of Rapport Therapeutics (NASDAQ:RAPP) StockMay 15, 2026 | americanbankingnews.comRapport Therapeutics (NASDAQ:RAPP) Major Shareholder Sells $5,376,788.32 in StockMay 14, 2026 | insidertrades.comRapport Therapeutics (NASDAQ:RAPP) Major Shareholder Rock Ventures L.P. Third Sells 5,018 Shares of StockMay 12, 2026 | americanbankingnews.comRock Ventures L.P. Third Sells 5,018 Shares of Rapport Therapeutics (NASDAQ:RAPP) StockMay 12, 2026 | insidertrades.comRapport Therapeutics (NASDAQ:RAPP) Major Shareholder Rock Ventures L.P. Third Sells 271,495 Shares of StockMay 12, 2026 | americanbankingnews.comSwedbank AB Buys Shares of 113,200 Rapport Therapeutics, Inc. $RAPPMay 10, 2026 | marketbeat.comBTIG Research Reiterates "Buy" Rating for Rapport Therapeutics (NASDAQ:RAPP)May 10, 2026 | americanbankingnews.comRapport Therapeutics (NASDAQ:RAPP) Raised to Hold at Wall Street ZenMay 9, 2026 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Posts Earnings Results, Beats Estimates By $0.25 EPSMay 8, 2026 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Receives Buy Rating from BTIG ResearchMay 8, 2026 | marketbeat.comRapport Therapeutics Advances RAP-219 Into Phase 3, Setting Up New Catalyst in Focal Seizure MarketMay 7, 2026 | tipranks.comRapport Therapeutics, Inc. (RAPP) Reports Q1 LossMay 7, 2026 | zacks.comRapport Therapeutics Reports First Quarter 2026 Financials and Provides Business UpdateMay 7, 2026 | globenewswire.comRapport Therapeutics Insiders Added US$1.61m Of Stock To Their HoldingsApril 30, 2026 | finance.yahoo.comModalités de mise à disposition du rapport financier annuel 2025April 30, 2026 | globenewswire.comMISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025April 30, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRAPP, KYMR, PTGX, and LNTH Company DescriptionsKymera Therapeutics NASDAQ:KYMR$80.65 +2.51 (+3.21%) Closing price 04:00 PM EasternExtended Trading$83.68 +3.04 (+3.76%) As of 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Lantheus NASDAQ:LNTH$96.09 +3.20 (+3.44%) Closing price 04:00 PM EasternExtended Trading$95.47 -0.62 (-0.65%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Protagonist Therapeutics NASDAQ:PTGX$100.88 +2.51 (+2.55%) Closing price 04:00 PM EasternExtended Trading$100.71 -0.17 (-0.17%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Rapport Therapeutics NASDAQ:RAPP$35.72 +1.35 (+3.93%) Closing price 04:00 PM EasternExtended Trading$35.69 -0.03 (-0.08%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook AI Consolidation Begins: Blackstone & Google Forge an AI Empire The Great AI Rotation: Cashing In on Data Mirum Pharma: A Rare Disease Growth Story to Watch Vertical Aerospace: Pre-Flight Checks Point to a Breakout HIVE Weaponizes Power for an AI Pivot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
